Crigler-Najjar syndrome
Crigler-Najjar syndrome
Explore linked clinical trials. Standard reference: MONDO:00090443 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gene Therapy for Crigler Najjar Syndrome Type I (AlphaCN) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crigler-Najjar syndrome, Nutritional and Metabolic Diseases, hereditary disease, hereditary hyperbilirubinemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 1 / Phase 2 | 2025-01-13 | NCT06641154 | |
| Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crigler-Najjar syndrome, Nutritional and Metabolic Diseases, hereditary disease, hereditary hyperbilirubinemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 2 | 2024-12-03 | NCT06518005 | |
| Gene Therapy for Severe Crigler Najjar Syndrome | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crigler-Najjar syndrome, Nutritional and Metabolic Diseases, hereditary disease, hereditary hyperbilirubinemia, inborn errors of metabolism, metabolic disease | Recruiting | Not applicable | 2023-03-28 | NCT03466463 |